查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965798

獸醫腫瘤市場－全球產業規模、佔有率、趨勢、機會、預測：按動物類型、治療類型、癌症類型、地區和競爭格局分類，2021-2031年

Veterinary Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type, By Treatment Type, By Cancer Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球獸醫腫瘤市場預計將從 2025 年的 18.2 億美元成長到 2031 年的 36.2 億美元，複合年成長率達 12.14%，實現了顯著成長。

該市場涵蓋了伴侶動物癌症管理的廣泛解決方案，包括診斷工具、外科手術以及化療和免疫療法等治療藥物。推動這一市場擴張的關鍵因素是老年寵物腫瘤疾病發生率的上升，以及由於人類與動物之間日益緊密的聯繫，飼主對專業醫療服務的需求不斷成長。此外，寵物保險產業的快速發展也提供了重要的資金支持。根據北美寵物健康保險協會 (NAPHIA) 統計，2024 年北美地區的寵物保險保費總額將達到 52 億美元。這些資金支持使得以往費用高昂的複雜腫瘤治療對寵物飼主來說更加經濟實惠。

市場概覽
預測期 2027-2031
市場規模：2025年 18.2億美元
市場規模：2031年 36.2億美元
複合年成長率：2026-2031年 12.14%
成長最快的細分市場 放射治療
最大的市場 北美洲

儘管前景樂觀，但高昂的治療費用仍是一大障礙，常常阻礙飼主主人制定長期治療方案。全球範圍內獸醫腫瘤專科醫生短缺，進一步加劇了這一經濟障礙。這種短缺限制了許多地區提供的專業服務，可能阻礙整體市場成長。因此，儘管需求不斷成長，但資金限制和專家短缺共同構成了獸醫腫瘤服務推廣和擴展的挑戰。

市場促進因素

伴侶動物癌症發生率的上升是全球獸醫腫瘤市場的主要驅動力。隨著寵物壽命因整體照護水準的提高而延長，腫瘤疾病的發生率自然也隨之上升，從而增加了對更頻繁、更先進的腫瘤治療的需求。近期流行病學數據也印證了這個趨勢。 2024年4月發表於PLOS One的一項研究估計，犬類腫瘤的發生率為每年每10萬隻高危險犬775例，其中皮膚腫瘤佔比最高，達34.64%。患者數量的增加得益於飼主醫療投入資金。根據美國寵物用品協會統計，截至2024年3月，美國獸醫保健及相關產品的年銷售額已達383億美元，顯示強勁的經濟基礎支撐著這些重要服務的廣泛普及。

同時，新型標靶治療和免疫療法的研發正在改變臨床實踐，並將市場格局從傳統化療轉向精準醫療。製藥和生物技術公司正積極利用人工智慧（AI）和基因組分析來設計個人化治療方案，以提高療效並最大限度地減少副作用。這項技術變革的影響在近期的臨床結果中顯而易見。根據Imprimed於2024年3月發布的報告，採用AI預測通訊協定治療高級別T細胞淋巴瘤犬的緩解率達到了59%，顯著高於低匹配組的9.1%。這些進展不僅提高了存活率，也展現了先進腫瘤解決方案的商業性潛力，並鼓勵企業持續加強研發投入。

市場挑戰

治療費用不斷上漲是全球獸醫腫瘤市場擴張的主要障礙。先進的癌症治療（包括診斷、特殊手術、長期化療等）費用高昂，往往超出許多寵物飼主的經濟承受能力。這種經濟差距常常迫使寵物主人放棄建議的腫瘤治療方案，轉而選擇費用較低的安寧療護或安樂死。這些經濟限制直接減少了複雜手術的數量，抑制了依賴先進療法廣泛應用的專業獸醫中心和藥物供應商的收入成長。

這種對成本的敏感度也體現在近期產業數據中，數據顯示消費者在動物保健方面的支出有所下降，尤其對高成本專科領域的影響更為顯著。根據美國獸醫協會（AVMA）預測，2024年獸醫總支出將年上年度4%。這主要是由於寵物飼主預算緊張所致。由於經濟可行性仍然是飼主決策的首要因素，因此這種支出能力的下降限制了昂貴腫瘤治療的潛在市場規模。因此，對於相當一部分寵物主人而言，價格高昂的有效癌症治療仍然難以負擔，從而限制了市場的成長潛力。

市場趨勢

液態生物檢體和非侵入性診斷檢測的出現，正徹底改變腫瘤疾病的檢測方式，使其從侵入性組織取樣轉向基於血液的生物標記篩檢。這種診斷方法使獸醫能夠在疾病早期識別循環腫瘤DNA和核小體，從而顯著提高預後和監測能力，且無需承擔切片檢查的風險。隨著這些便利的篩檢工具被納入老年寵物的常規健康檢查，其商業性應用正在加速發展。例如，VolitionRx公司報告稱，僅在2024年12月的第三季度，其Nu.Q Vet癌症篩檢試劑盒的銷量就達到了約5萬份，這凸顯了市場對可靠的非侵入性診斷解決方案的強勁需求。

同時，立體定位和移動放射治療技術的進步正在改變治療通訊協定，使高劑量輻射能夠以亞毫米級的精度進行傳輸。與需要在數週內進行多次麻醉的傳統分次放射治療不同，立體定位放射放射線手術(SRS) 和立體定位局部放射治療 (SBRT) 通常只需一到三次療程即可完成治療，從而減輕患者的壓力和麻醉相關的風險。這項技術進步擴大了可治療的患者群體，包括以前被認為無法切除或對傳統治療方法過於脆弱的病例。正如 Thrive Pet Healthcare 在 2024 年 4 月宣布的那樣，其專業合作夥伴 PetCure Oncology 已為超過 8,000 隻寵物實施了這些先進的放射線治療，取得了重要的臨床里程碑，凸顯了人們對精準高效治療方法的日益依賴。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球獸醫腫瘤市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 動物種類（狗、貓、其他）
    • 治療方法（放射線治療、手術、化療、其他）
    • 癌症類型（皮膚癌、淋巴瘤、肉瘤、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美獸醫腫瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲獸醫腫瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區獸醫腫瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲獸醫腫瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲獸醫腫瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球獸醫腫瘤市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim International GmbH
  • Zoetis Inc.
  • Elekta AB
  • PetCure Oncology
  • Accuray Incorporated
  • Varian Medical Systems, Inc.
  • Virbac SA
  • Merck & Co., Inc.
  • Dechra Pharmaceuticals PLC
  • NovaVive Inc.
  • Ardent Animal Health, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27376

The Global Veterinary Oncology Market is projected to experience substantial growth, expanding from USD 1.82 Billion in 2025 to USD 3.62 Billion by 2031, reflecting a compound annual growth rate of 12.14%. This market covers a wide spectrum of cancer management solutions for companion animals, including diagnostic tools, surgical interventions, and therapeutic agents such as chemotherapy and immunotherapy. The primary drivers of this expansion are the increasing incidence of neoplastic diseases among aging pet populations and the strengthening bond between humans and animals, which encourages owners to seek specialized medical care. Additionally, the rapid growth of the pet insurance sector serves as a crucial financial enabler; the North American Pet Health Insurance Association reported that total premium volume in North America reached $5.2 billion in 2024. This financial support makes complex oncological procedures more affordable for pet owners who previously found them cost-prohibitive.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.82 Billion
Market Size 2031USD 3.62 Billion
CAGR 2026-203112.14%
Fastest Growing SegmentRadiotherapy
Largest MarketNorth America

Despite this positive outlook, the market encounters significant obstacles due to high treatment costs, which frequently deter owners from committing to long-term care plans. This economic barrier is further complicated by a global shortage of board-certified veterinary oncologists. This scarcity limits the availability of specialized services in many geographic regions, potentially restricting broader market growth. Consequently, while demand is rising, the combination of financial constraints and a limited specialist workforce presents a challenge to the widespread accessibility and expansion of veterinary oncology services.

Market Driver

The escalating prevalence of cancer in companion animals acts as the primary catalyst for the Global Veterinary Oncology Market. As improvements in general care extend pet lifespans, the incidence of neoplastic diseases has naturally increased, creating a greater need for frequent and sophisticated oncological interventions. This trend is substantiated by recent epidemiological data; a study published in PLOS One in April 2024 calculated the overall tumor incidence rate in dogs at 775 per 100,000 dog-years at risk, with skin tumors constituting the largest category at 34.64% of cases. This rising patient volume is supported by an increase in owner spending power and a willingness to invest in medical outcomes. According to the American Pet Products Association, annual U.S. veterinary care and product sales hit $38.3 billion in March 2024, demonstrating a strong financial ecosystem that facilitates the adoption of these critical services.

Simultaneously, the development of novel targeted therapies and immunotherapies is transforming the clinical landscape, shifting the market focus from traditional chemotherapy toward precision medicine. Pharmaceutical and biotech companies are increasingly utilizing artificial intelligence and genomic profiling to design tailored treatment regimens that offer improved efficacy with fewer side effects. The impact of this technological shift is evident in recent clinical results; according to ImpriMed in March 2024, dogs with high-grade T-cell lymphoma treated with AI-predicted protocols achieved a remission rate of 59%, significantly surpassing the 9.1% remission rate seen in the low-matching group. These advancements not only enhance survival rates but also validate the commercial potential of sophisticated oncological solutions, encouraging continued investment in research and development.

Market Challenge

Prohibitive treatment expenses constitute a major barrier to the expansion of the Global Veterinary Oncology Market. The high costs associated with advanced cancer care, spanning diagnostics, specialized surgeries, and long-term chemotherapy, often exceed the financial means of many pet owners. This economic gap frequently forces clients to decline recommended oncological interventions in favor of less expensive palliative options or euthanasia. Such financial limitations directly reduce the volume of complex procedures performed, thereby suppressing revenue growth for specialized veterinary centers and pharmaceutical suppliers that depend on the widespread adoption of these advanced therapies.

This sensitivity to cost is mirrored in recent industry data showing a contraction in consumer spending on animal healthcare, which disproportionately impacts high-cost specialties. According to the American Veterinary Medical Association, overall veterinary spending dropped by 4% in 2024 compared to the previous year as pet owners faced tighter budgets. This reduction in spending capacity limits the addressable market for expensive oncology treatments, as financial feasibility remains a primary decision-making factor for clients. Consequently, the market faces capped growth potential, as the high price point of effective cancer management renders it inaccessible to a significant segment of the pet-owning population.

Market Trends

The emergence of liquid biopsy and non-invasive diagnostic testing is revolutionizing the detection of neoplastic diseases by moving away from invasive tissue sampling toward blood-based biomarker screening. This diagnostic method enables veterinarians to identify circulating tumor DNA or nucleosomes at earlier stages of disease, significantly enhancing prognostic accuracy and monitoring capabilities without the risks associated with surgical biopsies. The commercial adoption of these accessible screening tools is accelerating as they become integrated into routine wellness exams for aging pets. For example, VolitionRx reported in December 2024 that it sold approximately 50,000 units of its Nu.Q Vet Cancer Screening Test in the third quarter alone, highlighting the robust market demand for reliable, non-invasive diagnostic solutions.

concurrently, advancements in stereotactic and mobile radiation therapy technologies are reshaping treatment protocols by allowing for the delivery of high-dose radiation with sub-millimeter precision. Unlike traditional fractionated radiotherapy that requires numerous anesthetic events over several weeks, stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) typically condense treatment into just one to three sessions, reducing patient stress and anesthesia-related risks. This technological evolution expands the treatable patient base to include cases previously considered unresectable or too medically fragile for conventional courses. According to Thrive Pet Healthcare in April 2024, its specialty partner PetCure Oncology achieved a significant clinical milestone by administering these advanced radiation therapies to over 8,000 pets, validating the growing reliance on precise, high-efficiency therapeutic modalities.

Key Market Players

  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim International GmbH
  • Zoetis Inc.
  • Elekta AB
  • PetCure Oncology
  • Accuray Incorporated
  • Varian Medical Systems, Inc.
  • Virbac S.A.
  • Merck & Co., Inc.
  • Dechra Pharmaceuticals PLC
  • NovaVive Inc.
  • Ardent Animal Health, LLC

Report Scope

In this report, the Global Veterinary Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Oncology Market, By Animal Type

  • Canine
  • Feline
  • Others

Veterinary Oncology Market, By Treatment Type

  • Radiotherapy
  • Surgery
  • Chemotherapy
  • Others

Veterinary Oncology Market, By Cancer Type

  • Skin Cancers
  • Lymphomas
  • Sarcomas
  • Others

Veterinary Oncology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Oncology Market.

Available Customizations:

Global Veterinary Oncology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Oncology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Canine, Feline, Others)
    • 5.2.2. By Treatment Type (Radiotherapy, Surgery, Chemotherapy, Others)
    • 5.2.3. By Cancer Type (Skin Cancers, Lymphomas, Sarcomas, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Veterinary Oncology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Cancer Type
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Veterinary Oncology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Treatment Type
        • 6.3.1.2.3. By Cancer Type
    • 6.3.2. Canada Veterinary Oncology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Treatment Type
        • 6.3.2.2.3. By Cancer Type
    • 6.3.3. Mexico Veterinary Oncology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Treatment Type
        • 6.3.3.2.3. By Cancer Type

7. Europe Veterinary Oncology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Cancer Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Veterinary Oncology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Cancer Type
    • 7.3.2. France Veterinary Oncology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Cancer Type
    • 7.3.3. United Kingdom Veterinary Oncology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Cancer Type
    • 7.3.4. Italy Veterinary Oncology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Treatment Type
        • 7.3.4.2.3. By Cancer Type
    • 7.3.5. Spain Veterinary Oncology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Treatment Type
        • 7.3.5.2.3. By Cancer Type

8. Asia Pacific Veterinary Oncology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Cancer Type
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Veterinary Oncology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Cancer Type
    • 8.3.2. India Veterinary Oncology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Cancer Type
    • 8.3.3. Japan Veterinary Oncology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Cancer Type
    • 8.3.4. South Korea Veterinary Oncology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Treatment Type
        • 8.3.4.2.3. By Cancer Type
    • 8.3.5. Australia Veterinary Oncology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Treatment Type
        • 8.3.5.2.3. By Cancer Type

9. Middle East & Africa Veterinary Oncology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Cancer Type
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Veterinary Oncology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Cancer Type
    • 9.3.2. UAE Veterinary Oncology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Cancer Type
    • 9.3.3. South Africa Veterinary Oncology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Cancer Type

10. South America Veterinary Oncology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Cancer Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Veterinary Oncology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By Cancer Type
    • 10.3.2. Colombia Veterinary Oncology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By Cancer Type
    • 10.3.3. Argentina Veterinary Oncology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Veterinary Oncology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Elanco Animal Health Incorporated
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Zoetis Inc.
  • 15.4. Elekta AB
  • 15.5. PetCure Oncology
  • 15.6. Accuray Incorporated
  • 15.7. Varian Medical Systems, Inc.
  • 15.8. Virbac S.A.
  • 15.9. Merck & Co., Inc.
  • 15.10. Dechra Pharmaceuticals PLC
  • 15.11. NovaVive Inc.
  • 15.12. Ardent Animal Health, LLC

16. Strategic Recommendations

17. About Us & Disclaimer